Condition: Gastric Cancer · Colon Cancer · Rectal Cancer · Sponsor: Chongqing Precision Biotech Co., Ltd
This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CART cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
This description comes directly from the study's public registry record.
lili Sheng, M.D · 13605535185 · shenglili@yjsyy.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Wannan Medical College | Wuhu, Anhui, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06126406